Universität zu Köln

Jenks, Jeffrey D., Reed, Sharon L., Seidel, Danila ORCID: 0000-0003-4388-3117, Koehler, Philipp ORCID: 0000-0002-7386-7495, Cornely, Oliver A., Mehta, Sanjay R. and Hoenigl, Martin ORCID: 0000-0002-1653-2824 (2018). Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int. J. Antimicrob. Agents, 52 (5). S. 706 - 713. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1872-7913

Full text not available from this repository.

Abstract

Non-Aspergillus invasive mould infections (IMIs) are associated with devastating morbidity and mortality rates and are increasingly diagnosed in immunocompromised hosts. The aim of this study was to describe the epidemiology and outcomes of non-Aspergillus IMIs at a university hospital in San Diego, California, USA. A retrospective chart review of the medical records of all patients with cultures growing non-Aspergillus moulds at the microbiology laboratory in the Center for Academic Laboratory Medicine, Department of Pathology, University of California, San Diego (UCSD) Health between mid-2014 and mid-2017 (3-year period) was performed. A total of 23 cases of non-Aspergillus IMI were identified, including 10 cases of mucormycosis, 8 cases of lomentosporiosis and 5 cases of fusariosis. Antifungal susceptibility testing was performed for 14 isolates, and 10/11 Fusarium and Lomentospora isolates had minimum inhibitory concentrations (MICs) of >16 mu g/mL for voriconazole and/or posaconazole. Overall 180-day mortality was significantly lower among those who received combination antifungal therapy than among those who received single-agent therapy [3/13 (23%) vs. 9/10 (90%); P = 0.003]. In conclusion, Lomentospora prolificans (35% of non-Aspergillus IMIs) and Fusarium spp. (22%) accounted for high proportions of non-Aspergillus IMIs during the study period. Non-Aspergillus IMIs were detected in patients with various underlying diseases and were associated with high mortality rates, which was significantly lower in those who received antifungal combination therapy. (C) 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Jenks, Jeffrey D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Reed, Sharon L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Seidel, Danila UNSPECIFIED orcid.org/0000-0003-4388-3117 UNSPECIFIED Koehler, Philipp UNSPECIFIED orcid.org/0000-0002-7386-7495 UNSPECIFIED Cornely, Oliver A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mehta, Sanjay R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoenigl, Martin UNSPECIFIED orcid.org/0000-0002-1653-2824 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-167895
DOI:	10.1016/j.ijantimicag.2018.08.005
Journal or Publication Title:	Int. J. Antimicrob. Agents
Volume:	52
Number:	5
Page Range:	S. 706 - 713
Date:	2018
Publisher:	ELSEVIER SCIENCE BV
Place of Publication:	AMSTERDAM
ISSN:	1872-7913
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language HEMATOPOIETIC STEM-CELL; INVASIVE ASPERGILLOSIS; TRANSPLANT RECIPIENTS; AMPHOTERICIN-B; IN-VITRO; POSACONAZOLE; MUCORMYCOSIS; GUIDELINES; MANAGEMENT; DIAGNOSIS Multiple languages Infectious Diseases; Microbiology; Pharmacology & Pharmacy Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/16789